Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX StudyJonathan W. Friedberg, Jeff P. Sharman, Gilles Salles et al.|Blood|2022Cited by 6
ABCL-1492: Mosunetuzumab Plus Polatuzumab Vedotin (MPola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO TrialJason R. Westin, Huilai Zhang, Won-Seog Kim et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
ORAL ABSTRACT: ABCL-1492 Mosunetuzumab Plus Polatuzumab Vedotin (M-Pola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO TrialJason R. Westin, Huilai Zhang, Won-Seog Kim et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0